| 82.93 -0.99 (-1.18%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 110.86  |
1-year : | 120.62 |
| Resists | First : | 94.92 |
Second : | 103.27 |
| Pivot price | 90.55 |
|||
| Supports | First : | 81.41 |
Second : | 67.73 |
| MAs | MA(5) : | 85.56 |
MA(20) : | 92.79 |
| MA(100) : | 103.33 |
MA(250) : | 92.73  |
|
| MACD | MACD : | -4.2 |
Signal : | -3.4 |
| %K %D | K(14,3) : | 4.1 |
D(3) : | 7.2 |
| RSI | RSI(14): 25.8 |
|||
| 52-week | High : | 130 | Low : | 63.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MIRM ] has closed above bottom band by 8.5%. Bollinger Bands are 0.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 85.23 - 86.05 | 86.05 - 86.55 |
| Low: | 79.69 - 80.75 | 80.75 - 81.39 |
| Close: | 81.71 - 83.44 | 83.44 - 84.49 |
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Fri, 02 Oct 2026
Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study - TradingView
Tue, 29 Sep 2026
Is Mirum Pharmaceuticals (MIRM) Undervalued On New Brelo Vitug Trial Data? - Yahoo Finance
Mon, 28 Sep 2026
MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy - easternprogress.com
Mon, 28 Sep 2026
Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment - Yahoo Finance
Mon, 28 Sep 2026
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 111.8 (%) |
| Shares Short | 6,490 (K) |
| Shares Short P.Month | 7,270 (K) |
| EPS | -14.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.16 |
| Profit Margin | -139.2 % |
| Operating Margin | -14.9 % |
| Return on Assets (ttm) | -6.8 % |
| Return on Equity (ttm) | -703 % |
| Qtrly Rev. Growth | 37.9 % |
| Gross Profit (p.s.) | 8.28 |
| Sales Per Share | 10.13 |
| EBITDA (p.s.) | -1.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -227 (M) |
| Levered Free Cash Flow | 77 (M) |
| PE Ratio | -5.89 |
| PEG Ratio | 0 |
| Price to Book value | -518.32 |
| Price to Sales | 8.18 |
| Price to Cash Flow | -22.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|